ArticleClinical immunology (Orlando, Fla.)2023
PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).
Article in Clinical immunology (Orlando, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL).Lupus science & medicine · 2026Article
- Clinicopathological Correlations, Treatment Response, and Predictors of Outcomes in Childhood Lupus Nephritis in China.International journal of rheumatic diseases · 2026Article
- Mental health monitoring in adolescents with SLE: associations with lupus low disease activity state and remission.Lupus science & medicine · 2026Article
- Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- [Joint patient-oriented care-First interdisciplinary S2-k guidelines on juvenile systemic lupus erythematodes].Zeitschrift fur Rheumatologie · 2026Review
- Insights into the pathogenesis of childhood-onset SLE in the past decade.Nature reviews. Rheumatology · 2026Review
- Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.Current rheumatology reports · 2025Review
- Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain.Lupus science & medicine · 2025Article
- Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients.Rheumatology (Oxford, England) · 2025Article
- Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes.Lupus science & medicine · 2025Article
- Mortality in children and adolescents with autoimmune inflammatory rheumatic diseases admitted to the pediatric intensive care unit.Pediatric rheumatology online journal · 2025Article
- Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale.ACR open rheumatology · 2025Article
- Childhood-Onset Systemic Lupus Erythematosus (cSLE): An International Perspective.Current allergy and asthma reports · 2024Review
- Active implementation of low disease activity state as a treatment endpoint in childhood-onset systemic lupus erythematosus in routine practice is both feasible and associated with better outcomes.Clinical rheumatology · 2024Article
- Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force.Clinical immunology (Orlando, Fla.) · 2024Article
- Long-term outcomes and predictive factors of achieving low disease activity status in childhood systemic lupus erythematosus: a Chinese bicentric retrospective registered study.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 16 institutions in 11 countries.
Funding
Abstract
objectiveTo achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials.
methodsThe International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria.
resultsThe Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0-3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics.
conclusionsA cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.